The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1169
November 10, 2003
View Complete Issue         Table of Contents 2019 
Growth Hormone for Normal Short Children
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Growth Hormone for Normal Short Children
November 10, 2003 (Issue: 1169)
The FDA has approved Humatrope, Lilly's brand of recombinant human growth hormone (somatropin), for long-term treatment of children with idiopathic, non-growth-hormone-deficient (NGHD) short stature who are more than 2.25 standard deviations below...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Growth Hormone for Normal Short Children
Article code: 1169a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.